Supernus Pharmaceuticals (SUPN) Other Non-Current Liabilities (2011 - 2026)

Supernus Pharmaceuticals (SUPN) has 16 years of Other Non-Current Liabilities data on file, last reported at $19.5 million in Q1 2026.

• Other Non-Current Liabilities for Q1 2026 came in at $19.5 million, up 161.5% year-over-year; the trailing twelve-month figure through Mar 2026 was $19.5 million (up 161.5% YoY), and the FY2025 annual result was $31.3 million, up 311.29% from the prior year.
• Other Non-Current Liabilities retreated to $19.5 million in Q1 2026 per SUPN's latest filing, from $31.3 million in the prior quarter.
• Over five years, Other Non-Current Liabilities peaked at $54.1 million in Q2 2023 and troughed at $213000.0 in Q3 2025.
• A 5-year average of $16.8 million and a median of $8.7 million in 2022 frame the typical range for Other Non-Current Liabilities.
• On a YoY basis, Other Non-Current Liabilities climbed as much as 664.75% in 2025 and fell as far as 99.55% in 2025.
• A 5-year view of Other Non-Current Liabilities shows it stood at $8.7 million in 2022, then plunged by 84.12% to $1.4 million in 2023, then surged by 450.72% to $7.6 million in 2024, then jumped by 311.29% to $31.3 million in 2025, then sank by 37.56% to $19.5 million in 2026.
• Business Quant data shows SUPN's Other Non-Current Liabilities at $19.5 million in Q1 2026, $31.3 million in Q4 2025, and $213000.0 in Q3 2025.